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The transcription factors Elk-1 and SAP-1 bind together with serum response factor to the serum response
element present in the c-fos promoter and mediate increased gene expression. The ERK, JNK, and p38 groups
of mitogen-activated protein (MAP) kinases phosphorylate and activate Elk-1 in response to a variety of
extracellular stimuli. In contrast, SAP-1 is activated by ERK and p38 MAP kinases but not by JNK. The
proinflammatory cytokine interleukin-1 (IL-1) activates JNK and p38 MAP kinases and induces the transcrip-
tional activity of Elk-1 and SAP-1. These effects of IL-1 appear to be mediated by Rho family GTPases. To
examine the relative roles of the JNK and p38 MAP kinase pathways, we examined the effects of IL-1 on CHO
and NIH 3T3 cells. Studies of NIH 3T3 cells demonstrated that both the JNK and p38 MAP kinases are
required for IL-1-stimulated Elk-1 transcriptional activity, while only p38 MAP kinase contributes to IL-1-
induced activation of SAP-1. In contrast, studies of CHO cells demonstrated that JNK (but not the p38 MAP
kinase) is required for IL-1-stimulated Elk-1-dependent gene expression and that neither JNK nor p38 MAP
kinase is required for IL-1 signaling to SAP-1. We conclude that (i) distinct MAP kinase signal transduction
pathways mediate IL-1 signaling to ternary complex transcription factors (TCFs) in different cell types and (ii)
individual TCFs show different responses to the JNK and p38 signaling pathways. The differential utilization
of TCF proteins and MAP kinase signaling pathways represents a potential mechanism for the determination
of cell-type-specific responses to extracellular stimuli.
Transcription of the prototypic immediate-early gene c-fos is
rapidly induced in cells treated with a wide variety of extracel-
lular stimuli, including growth factors, cytokines, UV radiation,
and phorbol ester. The serum response element (SRE) is an
important regulatory sequence located in the c-fos promoter
(75) and is a target for a number of signal transduction path-
ways (7, 8, 81). The SRE is recognized by a complex of serum
response factor (SRF) and a ternary complex factor (TCF)
(76).
SRF is phosphorylated in vitro by casein kinase II, the ERK-
activated S6 kinase p90rsk, and a DNA-activated protein kinase
(8). However, the role of these kinases in the transcriptional
activation of SRF remains unclear. Calcium activates SRF-
dependent transcription independently of TCF, by a mecha-
nism involving Ca21/calmodulin-dependent protein kinases
(51). A recent study has provided evidence that members of
the Ras-related Rho family of GTPases are involved in signal-
ing pathways that lead to SRF-mediated activation of the c-fos
SRE independently of complex formation with TCFs (27). This
family of GTPases includes Cdc42, Rac1, and RhoA. These
GTPases play a critical role in regulating the actin cytoskeleton
and other physiological processes (60). RhoA is important for
SRF-mediated induction of the c-fos SRE by serum, lysophos-
phatidic acid, and aluminum fluoride (27). Activated mutants
of Cdc42 and Rac1 have been proposed to stimulate SRF-
mediated transcription independently of TCFs (27). The sig-
naling mechanisms involved in these events await elucidation.
TCF proteins belong to a subgroup of the Ets domain family
(33) that includes Elk-1 (28), SAP-1 (13), and SAP-2 (21, 44,
54). The primary sequences of these proteins show significant
similarity in three distinct regions (76). The N-terminal 93
amino acids comprise the Ets domain, which mediates DNA
binding (13, 32, 70). The more centrally located 21-amino-acid
B box is required for ternary complex formation and has been
demonstrated to mediate direct protein-protein contacts be-
tween Elk-1 and SRF (69). The COOH-terminal activation
domain contains several conserved mitogen-activated protein
(MAP) kinase phosphorylation sites (76). Phosphorylation of
the TCF proteins Elk-1 and SAP-1 on sites within the C-
terminal activation domain results in activated SRE-dependent
gene expression (7, 8, 81).
MAP kinases are proline-directed Ser/Thr protein kinases
that are regulated by extracellular signals including growth
factors, mitogens, and cellular stress (14, 15, 81). The best-
characterized MAP kinase subfamily includes ERK1 and
ERK2, which are activated by growth factors via the conserved
Ras/Raf-1/MEK pathway (15, 81). Recently, three distinct
stress-activated MAP kinase subfamilies have been identified:
JNK (also termed SAPK) (16, 22, 34, 38, 71), p38 (also termed
CSBP) (24, 39), and BMK1 (also termed ERK5) (1, 40, 87).
The JNKs were initially characterized by their ability to phos-
phorylate and activate the transcription factor c-Jun (16, 26,
38). The transcription factor ATF2 is also a target of JNK
MAP kinase (23, 43, 77). p38 MAP kinase phosphorylates and
activates ATF2 (57, 58) and CHOP (78). Components of the
kinase cascade that leads to JNK activation have been identi-
fied and include the MEK homolog MKK4 (also termed SEK1
or JNKK) (17, 41, 64) and the MAP kinase kinase kinases
MEKK1 (50, 84), MEKK2 (4), MEKK3 (4), Tpl-2 (63), SPRK/
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MLK3 (59, 74), and MUK (29). The MEK homologs MKK3
(17) and MKK6 (25, 52, 58, 72) activate p38 MAP kinase. A
candidate MAP kinase kinase kinase for p38 MAP kinase is
TAK1 (83), which activates both MKK3 and MKK6 (52). TAK1
is activated by TAK1-binding protein and has been proposed
to mediate transforming growth factor b signal transduction
(67).
It is established that Rho family GTPases are important for
cytoskeletal regulation (60) and the transforming activity of
oncogenic Ras (35, 36, 55, 56). Significantly, the full malignant
transformation activity of Ras requires the coordinate activity
of the Raf-1/MEK/ERK MAP kinase pathway and a pathway
mediated by the Rho family GTPases Rac and Rho (36, 55,
56). Recently, the Rho family GTPases Cdc42 and Rac1 have
been shown to stimulate the stress-activated MAP kinase path-
ways that lead to JNK and p38 MAP kinase activation (2, 11,
49, 53, 86).
A group of STE20-related serine/threonine kinases termed
PAKs (p21-activated kinases) are direct targets for activation
by Cdc42 and Rac1 (3, 5, 37, 45, 48) and appear to be inter-
mediates between the GTPases and the MAP kinase cascades
(3, 5, 86). Rho family GTPases and PAKs have been proposed
to mediate the activation of JNK and p38 MAP kinases by the
proinflammatory cytokine interleukin-1 (IL-1) (2, 86). Small
GTPases also directly activate MAP kinase kinase kinases. For
example, Ras binds to Raf-1 (81) and MEKK1 (61), and
SPRK/MLK3 binds Cdc42 and Rac (6, 59, 74).
The TCF protein Elk-1 is phosphorylated by the ERK (18,
19, 31, 47) and JNK (9, 10, 20, 82, 88) groups of MAP kinases
in response to growth factors, phorbol ester, IL-1, UV radia-
tion, and treatment with the protein synthesis inhibitor aniso-
mycin. ERK and JNKMAP kinases phosphorylate a similar set
of sites within the Elk-1 activation domain (10, 20, 82), leading
to increased DNA binding (66, 82), ternary complex formation
(18–20, 82), and transcriptional activation (10, 18, 20, 31, 47,
82). Recently, it has been demonstrated that p38 MAP kinase
phosphorylates Elk-1 in vitro and increases both Elk-1 tran-
scriptional activity and SRE-dependent gene expression (58).
SAP-1 activity is regulated by the ERK MAP kinase (30, 54,
70).
This study examines the role of the p38 and JNK MAP
kinase signal transduction pathways in the regulation of the
TCF transcription factors Elk-1 and SAP-1 in response to IL-1.
We show that both Elk-1 and SAP-1 are phosphorylated by p38
MAP kinase, leading to increased DNA binding activity, ter-
nary complex formation, and transcriptional activation. JNK
MAP kinase phosphorylates and activates Elk-1 but not SAP-1.
We used selective inhibitors of the JNK and p38 MAP kinase
pathways to demonstrate that in CHO cells, the JNK signaling
pathway is required to mediate IL-1-induced transcriptional
activity of Elk-1 (but not SAP-1) and SRE-dependent gene
expression. The IL-1-stimulated Elk-1 transcriptional activity
in CHO cells was blocked by dominant-negative Rho family
GTPases. Furthermore, we demonstrate that activated mu-
tants of the Rho family GTPases increase Elk-1 activity and
SRE-dependent gene expression in CHO cells and, in partic-
ular, that Cdc42-activated Elk-1-dependent reporter gene ex-
pression requires the JNK MAP kinase signal transduction
pathway. Finally, in contrast to the results obtained for CHO
cells, we show that in NIH 3T3 cells, IL-1-stimulated transcrip-
tional activity of Elk-1 requires both the p38 and JNK MAP
kinase signaling pathways, while p38 MAP kinase is essential
for SAP-1-dependent gene expression.
These data implicate roles for both the JNK and p38 signal-
ing pathways in mediating the transmission of extracellular
signals to the TCF component of the ternary complex at the
c-fos SRE. The relative importance of the JNK and p38 path-
ways is not conserved but depends on the cell type that is
examined.
MATERIALS AND METHODS
Materials. Plasmids J3HCdc42L61 and J3HCdc42N17, expressing hemagglu-
tinin (HA)-tagged constitutively activated Cdc42 L61 and inactivated Cdc42 N17,
were provided by R. A. Cerione (2). Plasmids pCDNA3/Rac1 L61, pCEV29/
Rac1 N17, pCDNA3/RhoA L63, and pCEV29/RhoA N19, expressing activated
and inactivated forms of Rac1 and RhoA, were provided by S. J. Gutkind (11).
pCMV5/Ras L61, expressing activated Ras, was a gift from L. Kozma (University
of Massachusetts Medical School). The vector pSG5 (Stratagene Inc.), which
expresses wild-type mouse MAP kinase phosphatase 1 (MKP1; 3CH134), was
provided by N. Tonks (73). Expression vectors for dominant-active MKK3
[MKK3(Glu)] (58), dominant-active MKK6 [MKK6(Glu)] (58), dominant-neg-
ative MKK4 (DN-MKK4) (82), MEKK1 (82), and activated MEK1 (DN3/S218E/
S222D MEK1) (46) have been described elsewhere. The expression vector for
HA-tagged ERK2 was provided by M. Weber (University of Virginia). HA-
tagged JNK1 (16), Flag-tagged JNK1 and JNK2 isoforms (16, 22, 71), and
Flag-tagged p38 (57) expression vectors have been described elsewhere. Vectors
expressing the GAL4 DNA binding domain (62), GAL4–Elk-1 (82), GAL4–
Elk-1 Ala-383 (82), GAL4–c-Jun (26), and GAL4–c-Jun Ala63/73 (26) have been
described elsewhere. The GAL4–SAP-1 expression vector was constructed by
subcloning a PCR fragment encoding SAP-1 residues 287 to 431 in the BamHI
and XbaI sites of pSG424 (62). The sequence of the construct was confirmed by
using a model 373A DNA sequencer (Applied Biosystems Inc.). Bacterial ex-
pression of glutathione S-transferase (GST)-tagged full-length ATF2 (23), GST-
ATF2 (residues 1 to 109) (23), GST–c-Jun (residues 1 to 79) (16), GST–Elk-1
(residues 307 to 428) (82), and GST–SAP-1 (residues 287 to 431) (82) has been
described previously. Bacterial expression of hexahistidine (His6)-tagged full-
length Elk-1 and SAP-1 has been described elsewhere (82). Rabbit polyclonal
antibodies that bind JNK and p38 MAP kinases have been described elsewhere
(57). Polyclonal antibodies that bind ERK1, ERK2, and JNK1 were purchased
from Santa Cruz Biotechnology. Mouse monoclonal M2 Flag antibody was from
IBI-Kodak. Mouse monoclonal anti-HA antibody was a gift from J. Pouysse´gur
(Centre National de la Recherche Scientifique, Nice, France). The p38 MAP
kinase inhibitor VK19577 (also termed SB203580 [12, 39]) was provided by
Vertex Pharmaceuticals Inc. and dissolved in dimethyl sulfoxide.
Tissue culture. Chinese hamster ovary (CHO) cells were maintained in Ham’s
F12 medium supplemented with 5% fetal bovine serum (Gibco-BRL). COS-7
cells and NIH 3T3 cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and 10% calf serum, respectively.
Plasmid DNA was transfected by the Lipofectamine method (Gibco-BRL). Cells
were harvested 48 h after transfection following serum starvation for 12 h. Where
indicated, CHO cells were treated with 10 ng of mouse IL-1a (Genzyme Corp.)
per ml, 10 nM tetradecanoyl phorbol acetate (Sigma), or 40 J of UV-C per m2.
Protein kinase assays. Cells were solubilized with Triton lysis buffer (20 mM
Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25
mM b-glycerophosphate, 1 mM sodium orthovanadate, 2 mM pyrophosphate, 1
mM phenylmethylsulfonyl fluoride, 10 mg of leupeptin per ml, 0.5 mM dithio-
threitol). The extracts were centrifuged at 14,000 3 g for 15 min at 48C. Endog-
enous ERK, JNK, and p38 were immunoprecipitated (3 h at 48C) from extracts
by using the appropriate polyclonal antibodies immobilized on protein A-Sepha-
rose (Sigma). Epitope-tagged ERK2, JNK1, and p38 were immunoprecipitated
with mouse monoclonal anti-HA or M2 Flag antibody immobilized on protein
G-Sepharose (Pharmacia-LKB Biotechnology). The immunoprecipitates were
washed three times with Triton lysis buffer and once with kinase buffer (25 mM
HEPES [pH 7.4], 25 mM b-glycerophosphate, 25 mM MgCl2, 0.5 mM dithio-
threitol, 0.1 mM sodium orthovanadate). The kinase assays were initiated by the
addition of 1 mg of substrate protein and 50 mM [g-32P]ATP (10 Ci/mmol) in a
final volume of 40 ml. The reactions were terminated after 30 min at 258C by the
addition of Laemmli sample buffer. The phosphorylation of substrate proteins
was examined after sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) by autoradiography.
Western blot analysis. HA-tagged JNK expression was detected by immuno-
blot analysis using a monoclonal anti-HA antibody. Immune complexes were
detected by enhanced chemiluminescence as instructed by the manufacturer
(Amersham International PLC).
Reporter gene expression. The activities of the GAL4 DNA binding domain,
GAL4–Elk-1, GAL4–Elk-1 Ala-383, GAL4–SAP-1, GAL4–c-Jun, and GAL4–c-
Jun Ala63/73 were measured in cotransfection assays in CHO cells with the
reporter plasmid pG5E1bLuc (65), which contains five GAL4 DNA binding sites
cloned upstream of a minimal promoter element and the firefly luciferase gene.
SRE-dependent gene expression was measured in cotransfection assays with the
reporter plasmid pSRE-Luc (65), which contains two copies of the c-fos SRE
cloned upstream of a minimal promoter element and the firefly luciferase gene.
Transfection efficiency was monitored by using a control plasmid expressing
b-galactosidase (pCH110; Pharmacia-LKB Biotechnology Inc.). The luciferase
and b-galactosidase activities were measured as described previously (65). The
data are presented as the ratio of luciferase activity to b-galactosidase activity.
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DNA binding assays. Electrophoretic mobility shift analysis (EMSA) was
performed with 32P-labeled E74 and SRE double-stranded oligonucleotide
probes and a 134-bp c-fos promoter fragment containing the SRE (SRE*) as
described previously (82). Phosphorylation of His6–Elk-1 and His6–SAP-1 was
performed with recombinant ERK2 and p38 MAP kinases activated in vitro by
the MAP kinase kinases MEK1 and MKK6, respectively. MEK1 was isolated
from epidermal growth factor-treated COS-7 cells with the rabbit polyclonal
antibody 2880 (79). Epitope-tagged MKK6(Glu) was isolated from transfected
COS-7 cells with the M2 Flag monoclonal antibody. Immune-complex kinase
assays were performed with MEK1 and MKK6(Glu), 6 mg of bacterially ex-
pressed GST-ERK2 or GST-p38, and 0.5 mg of either His6–Elk-1 or His6–SAP-1
in 20 ml of kinase buffer supplemented with 50 mM ATP for 30 min at 228C. The
following amounts of phosphorylated Elk-1 and SAP-1 were used in DNA bind-
ing assays: 5 ng of Elk-1 and SAP-1 with the E74 probe, 6.25 ng of Elk-1 and 12
ng of SAP-1 with the SRE probe, and 2.5 ng of Elk-1 and 10 ng of SAP-1 with
the SRE* probe. Binding reactions on SRE-containing sites also contained
purified bacterially expressed coreSRF (19). Control experiments were done
without ATP or MAP kinase kinase or MAP kinase. Protein-DNA complexes
were analyzed by PAGE (5% gel) in 0.53 Tris-borate-EDTA and visualized by
autoradiography.
RESULTS
Phosphorylation of Elk-1 and SAP-1 by p38 MAP kinase.
We have previously demonstrated that JNK MAP kinase effi-
ciently phosphorylates Elk-1 in vitro, while SAP-1 is poorly
phosphorylated (82). Moreover, the COOH-terminal activa-
tion domain of Elk-1 is a target for p38 MAP kinase (58).
Here, we tested the ability of p38 MAP kinase to phosphory-
late both full-length Elk-1 and SAP-1 and the COOH-terminal
activation domains of these TCF proteins (Fig. 1). Both Elk-1
and SAP-1 are efficient substrates for p38 MAP kinase. The
transcription factor ATF2, which is phosphorylated and acti-
vated by p38 MAP kinase (57, 58), was used as a positive con-
trol in these assays (Fig. 1). These data, together with our pre-
vious observations (58, 82), suggest that the p38 MAP kinase
signal transduction pathway targets both Elk-1 and SAP-1,
while the JNK signal transduction pathway selectively targets
Elk-1.
Phosphorylation of Elk-1 and SAP-1 by p38 MAP kinase
causes increased ternary complex formation and DNA binding
activity. Phosphorylation of Elk-1 and SAP-1 by ERK MAP
kinase, and phosphorylation of Elk-1 by JNK MAP kinase,
causes an increase in ternary complex formation with SRF at
the SRE and decreased ternary complex electrophoretic mo-
bility on a c-fos promoter fragment (19, 66, 70, 82). To test
whether p38 MAP kinase also regulates ternary complex for-
mation by phosphorylation of Elk-1 and SAP-1, EMSA was
performed. Experiments with an SRE oligonucleotide probe
demonstrated that p38 MAP kinase phosphorylation of Elk-1
and SAP-1 caused an increase in ternary complex formation
with coreSRF (Fig. 2A, lane 8; Fig. 2B, lane 8), similar to that
caused by ERK2 (Fig. 2A, lane 4; Fig. 2B, lane 4). Experiments
using a 134-bp fragment of the c-fos promoter that includes the
SRE demonstrated ternary complex formation in the absence
of TCF phosphorylation (Fig. 2C, 38I). Phosphorylation of
Elk-1 and SAP-1 by p38 and ERK2 MAP kinases caused de-
creased electrophoretic mobility of the ternary complex (Fig.
2C, 38II). These data indicate that p38 and ERK2MAP kinases
cause similar changes in ternary complex formation at the
SRE.
Elk-1 binds to certain ets-like DNA sequences indepen-
dently of SRF. This binding is regulated by ERK and JNK
MAP kinases (66, 82). SAP-1 binding to similar sequences is
regulated by ERKMAP kinase (70). We examined the effect of
p38 MAP kinase phosphorylation of Elk-1 and SAP-1 on their
ability to bind to a DNA probe containing the Drosophila E74
ets-like site. p38 MAP kinase caused enhanced DNA binding
activity of Elk-1 and SAP-1 (Fig. 2A, lane 16; Fig. 2B, lane 16)
comparably to ERK2 (Fig. 2A, lane 12; Fig. 2B, lane 12). These
data demonstrate that p38 MAP kinase, like ERK MAP ki-
nase, causes increased Elk-1 and SAP-1 DNA binding activity
in the absence of SRF.
While ERK and p38 MAP kinase phosphorylation of Elk-1
and SAP-1 increases both ternary complex formation on the
SRE oligonucleotide probe and E74-DNA binding activity
(Fig. 2A and B), some ternary complex formation and E74-
DNA binding was observed in the absence of phosphorylation
in these assays. This is particularly evident for complexes
formed with SAP-1 at the SRE (Fig. 2B, lanes 2 and 6). The
likely explanation is that SAP-1 binds to the SRE with higher
affinity than Elk-1 and forms more stable ternary complexes
(70). In addition, the binding of MAP kinases to the TCFs (20,
85) may cause some enhancement of DNA binding and ternary
complex formation in the absence of ATP by inducing confor-
mational changes in the TCFs.
The drug VK19577 inhibits the activity of p38 MAP kinase
and specific JNK MAP kinase isoforms in vitro. The drug
VK19577 (also termed SB203580 [12, 39]) is a recently de-
scribed inhibitor of p38 MAP kinase. To determine the use-
fulness of the drug VK19577 as a tool for examining the MAP
kinase signal transduction pathways that target Elk-1 and
SAP-1 in response to extracellular stimuli, we tested this drug
for its ability to inhibit p38, ERK, and JNK MAP kinase ac-
tivities in vitro. Nonactivated and activated epitope-tagged
MAP kinases were immunoprecipitated from CHO cells and
used in kinase assays with the substrate GST–Elk-1 (residues
310 to 428). A range of drug concentrations was included in the
assays; 0.1 mM drug reduced p38 MAP kinase activity by more
than 50%, 1 mM drug reduced activity to basal levels, and
higher concentrations almost abolish activity (Fig. 3A). This
inhibition of p38 is consistent with previous reports demon-
strating the strong inhibitory effect of this drug on p38 MAP
FIG. 1. TCFs are phosphorylated by p38 MAP kinase. The phosphorylation
of Elk-1 and SAP-1 by p38 MAP kinase was examined by immune-complex
protein kinase assay. Epitope-tagged p38 MAP kinase was immunopurified from
unactivated (2) and activated COS-7 cells (40 J of UV-C per m2) (1), using the
Flag monoclonal antibody (M2). Kinase assays were performed with the follow-
ing substrates: 0.5 mg of full-length proteins, His–Elk-1, His–SAP-1, and GST-
ATF2 (A) and 1 mg of activation domains. GST–Elk-1 (residues 310 to 428),
GST–SAP-1 (residues 287 to 431), and GST-ATF-2 (residues 1 to 109) (B). The
assays were terminated after 30 min at 228C, and the reaction products were
examined by SDS-PAGE and autoradiography. Molecular masses are shown in
kilodaltons. The full-length ATF-2 fusion protein with GST is expressed as a
doublet (A).
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kinase activity in vitro (12). ERK2 MAP kinase activity was
only slightly reduced over the range of drug concentrations test-
ed (Fig. 3A). However, the drug selectively inhibited the activ-
ity of JNKMAP kinase isoforms (Fig. 3B and C). The activities
of the JNK2 isoforms JNK2b1 and JNK2b2 (22) were reduced
to basal levels by 10 to 20 mM drug (Fig. 3C). The activities of
the JNK2 isoforms JNK2a1 and JNK2a2 (22) were also re-
duced by increasing concentrations of drug but required a 10-
fold-higher concentration of drug to be reduced to basal levels
(Fig. 3C). The drug was a less potent inhibitor of JNK1 iso-
forms but displayed some selectivity for inhibition of JNK1a1
and JNK1a2 (22) compared with JNK1b1 and JNK1b2 (22)
(Fig. 3B).
These data indicate that the drug VK19577 inhibits the ac-
tivities of both p38 MAP kinase and particular JNK MAP
kinase isoforms in vitro. However, at least 20-fold-higher con-
centrations of the drug were required to inhibit JNK isoforms
compared with p38 MAP kinase. Careful titration of the drug
is therefore necessary to observe specific inhibition of p38
MAP kinase activity.
FIG. 2. Phosphorylation of Elk-1 and SAP-1 by p38 MAP kinase causes increased ternary complex formation and increased DNA binding activity. Elk-1 and SAP-1
were phosphorylated in vitro by bacterially expressed p38 and ERK2 which were activated by MKK6 and MEK, respectively, immunopurified from UV-irradiated or
epidermal growth factor-treated COS-7 cells. (A) Ternary complex formation by Elk-1, SRF, and the SRE was measured by EMSA using a double-stranded 32P-labeled
oligonucleotide probe. The binary SRF-SRE complex (28) and the ternary complex (38) are indicated. DNA binding activity of Elk-1 was measured by EMSA using
a double-stranded E74 probe that contains an ets-like binding site. The Elk-1–E74 complex is indicated (28). (B) Ternary complex formation and DNA binding by SAP-1,
using the oligonucleotide probes used for panel A. (C) Ternary complex formation by Elk-1 and SAP-1 with SRF and a 134-bp fragment of the c-fos promoter containing
the SRE (SRE*). The binary SRF-SRE complex (28) and the two ternary complexes (38I and 38II) are indicated.
FIG. 3. Differential effects of the drug VK19577 on p38 (A), ERK (A), and JNK (B and C) MAP kinase activities in vitro. Epitope-tagged p38 (Flag), ERK2 (HA),
and JNK MAP kinase isoforms (Flag) (22) were immunopurified from transiently transfected COS-7 cells activated with 40 J of UV-C per m2 (p38 and JNK) or 10
nM tetradecanoyl phorbol acetate (ERK2). The kinases were incubated with 2 mg of GST–Elk-1 (residues 310 to 428) and 0, 0.1, 1, 10, 20, or 100 mM VK19577 (Drug)
for 20 min at 228C. The reaction products were examined by SDS-PAGE and autoradiography. The kinase activities were quantified with a PhosphorImager (Molecular
Dynamics). The kinase activities immunopurified from activated cells not treated with drug are given a value of 100%. A similar profile of MAP kinase activities was
observed in an independent experiment.
VOL. 17, 1997 p38 AND JNK MAP KINASES IN ACTIVATION OF TCFs 2363
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
The drug VK19577 inhibits activation of Elk-1 and SAP-1 by
the p38 MAP kinase signal transduction pathway in vivo. To
determine the specificity of the drug VK19577 in blocking the
p38 MAP kinase signal transduction pathway in vivo, we ex-
amined its effect on GAL4-Elk-1- and GAL4–SAP-1-depen-
dent reporter gene expression in CHO cells transfected with
expression constructs for MEKK1, activated MEK1, activated
MKK6 [MKK6(Glu)], and activated MKK3 [MKK3(Glu)]/p38
(Fig. 4). MEKK1, MEK1, and MKK6(Glu) have been demon-
strated to activate JNK (50, 84), ERK (15, 81), and p38 (25,
52, 58, 72) MAP kinases, respectively. MKK3(Glu) does not
appear to activate endogenous p38 but does activate p38 ex-
pressed in cotransfection experiments (58). GAL4-Elk-1- and
GAL4-SAP-1-dependent reporter gene expression was increased
by coexpression with MEKK1, activated MEK1, MKK6(Glu),
and MKK3(Glu)/p38 (Fig. 4). The addition of 10 mM drug
VK19577 to the culture medium inhibited MKK6(Glu)- and
MKK3(Glu)/p38-stimulated reporter gene expression but had
no effect on MEKK1- and MEK1-stimulated reporter gene
expression (Fig. 4). Mutation of the MAP kinase phosphory-
lation site previously demonstrated to be critical for full Elk-1
transcriptional activity (Ser-383 replaced with Ala) resulted in
the loss of MEKK1-, MEK1-, MKK6(Glu)-, and MKK3(Glu)/
p38-stimulated Elk-1-dependent reporter gene expression (Fig.
4). These data demonstrate that 10 mM VK19577 blocks p38
MAP kinase signaling but not the JNK or ERK signal trans-
duction pathways in vivo. Therefore, we used 10 mM VK19577
to selectively inhibit the p38 MAP kinase pathway in further
experiments.
p38 MAP kinase is not essential for IL-1-induced Elk-1 and
SAP-1 transcriptional activity in CHO cells. The proinflam-
matory cytokine IL-1 activates both the JNK and p38 MAP
kinase signaling pathways (57). We have previously shown that
IL-1 activates GAL4–Elk-1-dependent reporter gene expres-
sion in CHO cells (82). To determine whether p38 MAP kinase
plays a critical role in mediating IL-1-stimulated TCF tran-
scriptional activity, the effect of the drug VK19577 on IL-1-
induced GAL4-Elk-1 and GAL4-SAP-1-dependent reporter
gene expression was examined. Figure 5A shows that IL-1-
induced Elk-1 and SAP-1 transcriptional activities were not
inhibited by this drug in CHO cells (Fig. 5A). These data
demonstrate that p38 MAP kinase is not essential for mediat-
ing IL-1 activation of the TCF proteins Elk-1 and SAP-1 in
CHO cells.
We have demonstrated previously that a mutationally inac-
tivated form of the JNK-activating kinase MKK4 (DN-MKK4)
behaves as a dominant-negative inhibitor of the JNK pathway
and blocks IL-1-induced GAL4–Elk-1-dependent reporter gene
expression in CHO cells (82). The mechanism of inhibition
FIG. 4. The drug VK19577 inhibits activation of Elk-1 and SAP-1 by the p38
MAP kinase signal transduction pathway in vivo. CHO cells were transfected
with the reporter plasmid pG5E1bLuc (0.25 mg), an expression vector for GAL4–
Elk-1, GAL4–Elk-1 Ala-383, or GAL4–SAP-1 (0.25 mg of each), and a vector
expressing either MKK3(Glu) (0.25 mg) and p38 (0.25 mg), MKK6(Glu) (0.1 mg),
MEKK1 (0.1 mg), or activated MEK1 (0.2 mg). The b-galactosidase expression
vector pCH110 was included as a control for transfection efficiency. The cells
were transferred 12 h following transfection to serum-free medium for 6 h and
then treated with 10 mM VK19577 (Drug) for 10 h or without drug (Control).
Cell extracts were prepared, and the luciferase and b-galactosidase activities
were measured. The relative luciferase activities (means 6 standard deviations;
n 5 3) are presented.
FIG. 5. p38 MAP kinase is not essential for IL-1-induced SRE-dependent
gene expression and Elk-1 and SAP-1 transcriptional activity in CHO cells. (A)
The p38 inhibitor drug VK19577 does not inhibit IL-1-induced Elk-1 and SAP-1
transcriptional activity in CHO cells. Cells were transfected with the reporter
plasmid pG5E1bLuc (0.25 mg), the b-galactosidase plasmid pCH110 (0.1 mg),
and a vector expressing either GAL4–Elk-1 or GAL4–SAP-1 (0.25 mg). Follow-
ing incubation in serum-free medium for 12 h, the cells were treated with 10 ng
of IL-1 per ml for 10 h with or without 10 mM VK19577 (Drug). The data are
presented as relative luciferase activities (means 6 standard deviations; n 5 3).
The effect of DN-MKK4 (0.5 mg of expression vector transfected) and DN-
MKK4 in combination with 10 mM VK19577 (Drug) on GAL4–Elk-1- and
GAL4–SAP-1-dependent reporter gene expression was examined in cells treated
with IL-1. (B) The p38 inhibitor drug VK19577 does not inhibit IL-1-induced
SRE-dependent reporter gene expression in CHO cells. Cells were transfected
with the pSRE-Luc reporter plasmid (1 mg) and pCH110 (0.25 mg). The cells
were incubated in serum-free medium for 12 h and then treated with 10 ng of
IL-1 per ml for 10 h without or with 10 mMVK19577 (Drug). Cotransfection with
the DN-MKK4 expression vector (0.5 mg) inhibited IL-1-induced SRE-depen-
dent reporter gene expression. The data are presented as relative luciferase
activities (means 6 standard deviations; n 5 3). (C) IL-1 activates p38 and JNK,
but not ERK, MAP kinase activity in CHO cells. Cells were incubated in serum-
free medium for 12 h and then treated without and with 10 ng of IL-1 per ml and
10 mMVK19577 (Drug) for 15, 30, and 60 min. The activities of endogenous p38,
JNK, and ERK MAP kinases were measured in immune-complex kinase assays
using the appropriate polyclonal antibodies and the respective substrates GST-
ATF2 (residues 1 to 109), GST–c-Jun (residues 1 to 79), and GST–Elk-1 (resi-
dues 310 to 428). The kinase activities were quantified by PhosphorImager
analysis, and the data are presented as relative MAP kinase activities compared
to kinase activities immunopurified from untreated cells. A similar profile of
MAP kinase activities was obtained in an independent experiment.
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caused by DN-MKK4 probably involves the interaction with
upstream (MAP kinase kinase kinases) or downstream (MAP
kinases) components of the JNK MAP kinase signaling path-
way. In transient transfection assays, DN-MKK4 had a small
inhibitory effect on IL-1-induced GAL4-SAP-1-dependent re-
porter gene expression but significantly inhibited GAL4-Elk-
1-dependent reporter gene expression. These data imply that
IL-1 signaling to SAP-1 and Elk-1 occurs via different signaling
pathways in CHO cells. The strong inhibitory effect of DN-
MKK4 on IL-1-induced Elk-1 transcriptional activity (Fig. 5A)
indicates a major role for the JNK MAP kinase signal trans-
duction pathway. The lack of inhibition of IL-1-induced SAP-1
transcriptional activity by either DN-MKK4 or the p38 inhib-
itor drug, individually or combined (Fig. 5A), suggests that
IL-1 signaling to SAP-1 is mediated by a novel kinase pathway
in CHO cells.
Elk-1 and SAP-1 are potential components of ternary com-
plexes formed with SRF at the SRE. To determine whether the
lack of inhibition of IL-1 signaling to Elk-1 or SAP-1 by the
drug VK19577 in CHO cells correlated with a similar lack of
inhibition of IL-1 signaling to ternary complexes at the SRE,
the effect of the drug on IL-1 signaling to tandem c-fos SREs
cloned upstream of a reporter gene was examined. The drug
did not inhibit SRE-dependent reporter gene expression (Fig.
5B). However, coexpression with DN-MKK4 did inhibit SRE-
dependent reporter gene expression (Fig. 5B). These data im-
ply that JNK, but not p38 MAP kinase, is required for IL-1
signaling to ternary complexes at the SRE in CHO cells.
To confirm which MAP kinases were activated by IL-1 in
CHO cells and also to examine the effect of the p38 inhibitor
drug VK19577 on the activation of the MAP kinases (as op-
posed to the effect on their kinase activities), CHO cells were
treated with or without IL-1 and the drug over a period of 60
min, and endogenous p38, JNK, and ERK MAP kinases were
immunoprecipitated, washed to remove the drug VK19577,
and assayed for kinase activity (Fig. 5C). p38 and JNK MAP
kinases were strongly activated by IL-1, while there was weak
activation of ERK MAP kinase (Fig. 5C). Inhibition of both
basal and IL-1-stimulated p38 MAP kinase activation was ob-
served (Fig. 5C). The drug VK19577 therefore blocks the p38
MAP kinase signaling pathway at two distinct steps: (i) by
inhibiting p38 MAP kinase activation (Fig. 5C) and (ii) by inhib-
iting p38 MAP kinase activity (Fig. 3A). JNK activation was not
inhibited by the drug. Indeed, the duration of JNK activation by
IL-1 was increased by treatment with the drug (Fig. 5C). The drug
also caused a small increase in ERK activation (Fig. 5C). The
drug therefore displays opposing effects on IL-1-stimulated p38
and JNK activation. It inhibits the activation of p38 MAP kinase
but prolongs the activation of JNK MAP kinase.
p38 MAP kinase is required for IL-1-induced Elk-1 and
SAP-1 transcriptional activity in NIH 3T3 cells.We have dem-
onstrated that in CHO cells, IL-1 signaling to the TCF protein
Elk-1 is primarily mediated by the JNK MAP kinase pathway
(Fig. 5). However, IL-1 may signal through different protein
kinase pathways in different cell types. For example, in COS-7
cells, IL-1 treatment causes significant activation of ERKMAP
kinase, which is known to regulate TCF transcriptional activity
(80). We therefore investigated IL-1 signaling pathways target-
ing TCFs in a different cell type. We chose NIH 3T3 cells for
these studies because this cell line has been extensively char-
acterized by examination of signaling pathways that converge
at the SRE (76). IL-1-stimulated GAL4–Elk-1- and GAL4–
SAP-1-dependent reporter gene expression was inhibited by
the drug VK19577 in NIH 3T3 cells (Fig. 6A). This observation
indicates that p38 MAP kinase is an important component of
signaling pathways that target the TCF proteins Elk-1 and
SAP-1 in response to IL-1 treatment of NIH 3T3 cells.
Coexpression of DN-MKK4 significantly inhibited GAL4–
Elk-1-dependent reporter gene expression but had only a small
inhibitory effect on GAL4–SAP-1-dependent reporter gene ex-
pression. This result is consistent with JNK MAP kinase being
required for IL-1 signaling to Elk-1 but not SAP-1. The inclu-
sion of both DN-MKK4 and the drug VK19577 resulted in a
further decrease in GAL4–Elk-1 transcriptional activity (Fig.
6A). Therefore, in NIH 3T3 cells, both JNK and p38 MAP
kinases are required for IL-1 signaling to Elk-1. Similar exper-
iments using the c-fos SRE reporter gene demonstrated that
both the drug VK19577 and DN-MKK4 cause some inhibition
of IL-1-induced reporter gene expression (Fig. 6B), indicating
that the JNK and p38 MAP kinase signaling pathways contrib-
ute to the regulation of the c-fos SRE in NIH 3T3 cells.
Control experiments were performed to examine the effect
of the drug VK19577 on IL-1-stimulated MAP kinase activa-
FIG. 6. p38 MAP kinase is required for IL-1-induced Elk-1 and SAP-1 tran-
scriptional activity in NIH 3T3 cells. (A) Cells were transfected with the reporter
plasmid pG5E1bLuc (0.25 mg), pCH110 (0.25 mg), and a vector expressing either
GAL4–Elk-1 or GAL4–SAP-1 (0.25 mg). Following incubation in serum-free
medium for 12 h, the cells were treated with 10 ng of IL-1 per ml for 10 h with
or without 10 mM VK19577 (Drug). Cotransfection of a vector expressing DN-
MKK4 (0.5 mg) was also examined. The data are presented as relative luciferase
activities (means 6 standard deviations; n 5 3). (B) The pSRE-Luc reporter
plasmid (1 mg) was cotransfected with or without a vector expressing DN-MKK4
(0.5 mg). The cells were incubated in serum-free medium for 12 h and then
treated with 10 ng of IL-1 per ml for 10 h without or with 10 mM VK19577
(Drug). (C) IL-1 activates JNK and p38 MAP kinase activities in NIH 3T3 cells.
Cells were incubated in serum-free medium for 12 h and then treated without
and with 10 ng of IL-1 per ml and 10 mM VK19577 (Drug). The activities of
endogenous p38, JNK, and ERK MAP kinases were measured by immune-
complex kinase assays using the appropriate polyclonal antibodies and the re-
spective substrates GST-ATF2 (residues 1 to 109), GST–c-Jun (residues 1 to 79),
and GST–Elk-1 (residues 310 to 428). The kinase activities were quantified by
PhosphorImager analysis, and the data are presented as relative MAP kinase
activities compared with untreated cells. A similar profile of MAP kinase activ-
ities was obtained in an independent experiment.
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tion in NIH 3T3 cells. Cells treated with the drug were incu-
bated with or without IL-1, and the endogenous p38, JNK, and
ERK MAP kinases were immunopurified and assayed for pro-
tein kinase activity. IL-1 activated both p38 and JNK MAP
kinases but not ERK MAP kinase (Fig. 6C). Addition of the
drug VK19577 inhibited p38 activation by IL-1 at 15 min but
appeared to increase IL-1-induced p38 activation following
further incubation (Fig. 6C). The reason for this biphasic ac-
tivation response is unclear. The enhancement of IL-1-induced
p38 activation caused by the drug VK19577 is negated by the
inhibition of p38 kinase activity caused by the drug. Similar to
its effect on CHO cells (Fig. 5C), the drug increased the du-
ration of JNK activation and also caused a small activation of
ERK MAP kinase.
These observations provide evidence that IL-1 signaling to
the TCF proteins Elk-1 and SAP-1 can be mediated by distinct
MAP kinase pathways in different cell types, for example,
CHO cells and NIH 3T3 cells.
Rho family GTPases regulate the activation of Elk-1- and
SRE-dependent gene expression via MAP kinase pathways in
CHO cells. Several recent studies have implicated members of
the Rho family of GTPases as components of the JNK and p38
MAP kinase signaling pathways (2, 11, 49, 53, 86). In addition,
it has been suggested that Rho family GTPases may mediate
IL-1 signaling events (2). To determine which MAP kinases are
activated by Rho family GTPases in CHO cells, we performed
a series of immune-complex kinase assays. Initially the abilities
of constitutively activated GTPases to stimulate transfected
epitope-tagged JNK1 protein kinase activity were tested. Ac-
tivated forms of Cdc42, Rac1, RhoA, and Ras were coex-
pressed with HA-tagged JNK1 in CHO cells. The HA-JNK1
was immunopurified from the cells by using an anti-HA mono-
clonal antibody and tested for kinase activity toward the sub-
strate GST–c-Jun (Fig. 7A). Activated Cdc42, Rac1, and Ras
increased HA-JNK1 activity, but RhoA did not. Immunoblots
of cell extracts prepared from the transfected cells indicate that
HA-JNK1 is expressed at similar levels when cotransfected
with each of the GTPases (Fig. 7A). The same experiment was
performed in COS-7 and NIH 3T3 cells with similar results
(80). These data confirm the results of previous studies per-
formed using COS, NIH 3T3, and HeLa cells (2, 11, 49, 53, 86).
A potential flaw in the cotransfection assays used to measure
MAP kinase activation by Rho family GTPases (Fig. 7A and
references 2, 11, 49, 53, and 86) is that the MAP kinases are
overexpressed. As MAP kinase activation is proposed to occur
within signaling modules that ensure specificity via protein-
protein interactions (14, 81), the regulation of overexpressed
MAP kinases may differ from regulation of MAP kinases ex-
pressed at physiological levels. We therefore performed a
more thorough series of experiments to assess the abilities of
Rho family GTPases to activate endogenous MAP kinases.
The Rho family GTPases were expressed in CHO cells, and the
endogenous ERK, JNK, and p38 MAP kinases were immuno-
purified with the appropriate polyclonal antibodies and used in
kinase assays with the substrates GST–Elk-1 (residues 310 to
428), GST–c-Jun (residues 1 to 79), and GST-ATF2 (residues
1 to 109), respectively. Activated Cdc42, Rac1, Ras, and RhoA
caused activation of endogenous JNK and p38 MAP kinases,
while only activated Ras increased endogenous ERK MAP
kinase activity (Fig. 7B). As only 10 to 20% of the cells are
transfected with activated GTPases and we are measuring en-
dogenous MAP kinase activities from the entire cell popula-
tion, the levels of MAP kinase activation that we observed are
likely to be a large underestimate of the true MAP kinase
FIG. 7. MAP kinase activation by Ras and Rho family GTPases. (A) Activation of transfected JNK by Rho family GTPases. CHO cells were transfected with vectors
expressing HA-JNK1 (0.5 mg) and either activated Rho family GTPases (0.5 mg) or activated Ras (0.1 mg). The expression levels of HA-JNK1 were monitored by
immunoblot analysis of cell lysates with an anti-HA monoclonal antibody (upper panel). HA-JNK1 activity was measured by immune-complex kinase assay using
GST–c-Jun as a substrate (lower panel). The kinase activities were quantitated with a PhosphorImager (Molecular Dynamics), and the data are presented as fold
stimulation compared to cells transfected with HA-JNK1 plasmid alone (Control). The experiment was repeated twice with similar results. (B) Activation of endogenous
MAP kinases by Rho family GTPases. CHO cells were transfected with plasmids expressing activated Rho family GTPases (0.5 mg) or activated Ras (0.1 mg).
Endogenous JNK, p38, and ERK activities were measured by immune-complex kinase assays using the substrates GST–c-Jun (residues 1 to 79), GST-ATF2 (residues
1 to 109), and GST–Elk-1 (residues 310 to 428), respectively. Kinase activities were quantitated with a PhosphorImager (Molecular Dynamics), and the results are
presented as fold stimulation compared to cells transfected with the empty expression vector (Control). The experiment was repeated twice with similar results. (C)
Rho family GTPases increase c-Jun transcriptional activity. Luciferase reporter gene expression was measured in extracts prepared from CHO cells transfected with
the pG5E1bLuc reporter plasmid (0.25 mg), the b-galactosidase expression plasmid pCH110 (0.1 mg), vectors expressing activated Rho family GTPases (0.5 mg), and
either GAL4–c-Jun or GAL4–c-Jun Ala63/73 (0.25 mg). The data are presented as relative luciferase activities (means 6 standard deviations; n 5 3).
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activation. These experiments demonstrate that RhoA acti-
vates the endogenous JNK and p38 MAP kinase signaling
pathways in CHO cells (Fig. 7B). This effect of RhoA is in
contrast to observations made for overexpressed JNK and p38
MAP kinases (Fig. 7A and references 11, 49, 53, and 86).
To test whether JNK activation by Rho family GTPases is
functionally coupled to a downstream signal transduction tar-
get, we examined the effects of expressing activated Rho family
GTPases on transcriptional activation by c-Jun. We found that
Cdc42, Rac1, and RhoA activated GAL4–c-Jun-dependent re-
porter gene expression (Fig. 7C). Mutation of the JNK MAP
kinase phosphorylation sites (Ser-63 and Ser-73) on c-Jun by
replacement with Ala blocked Rho family GTPase stimulation
of GAL4–c-Jun transcriptional activity (Fig. 7C). These data
demonstrate that the JNK MAP kinase signal transduction
pathway may mediate Cdc42, Rac1, and RhoA regulation of
c-Jun transcriptional activity in CHO cells and support the
conclusion that RhoA, like other Rho family GTPases, acti-
vates the JNK signaling pathway (Fig. 7B). This conclusion
contrasts with inferences drawn from experiments using over-
expressed JNK (Fig. 7A and references 11, 49, and 53).
SRE-dependent gene expression is increased following
MAP kinase phosphorylation and activation of TCF proteins
within the ternary complex (7, 8, 81). However, it has been
reported that activated forms of Cdc42, Rac1, and RhoA in-
crease SRF-dependent transcriptional activity independently
of ERK, JNK, and p38 MAP kinases and that these GTPases
are not relevant to the regulation of Elk-1 transcriptional ac-
tivity (27). To determine whether Cdc42, Rac1, and RhoA are
components of MAP kinase signaling pathways leading to
SRE-dependent gene expression in CHO cells, plasmids ex-
pressing activated forms of these GTPases were cotransfected
together with the pSRE-Luc reporter plasmid. All three Rho
family GTPases activated SRE-dependent gene expression
(Fig. 8A). Coexpression of MKP1 in these experiments led to
inhibition of SRE-dependent gene expression caused by acti-
vated Rho family GTPases (Fig. 8A). These data indicate that
MAP kinase pathways contribute to the activation of SRE-
dependent gene expression stimulated by Rho family GTPases
in CHO cells.
To examine whether Rho family GTPases can regulate Elk-1
transcriptional activity via MAP kinase pathways in CHO cells,
we coexpressed activated forms of the Rho family GTPases
together with MKP1, GAL4–Elk-1, and the reporter plasmid
pG5E1bLuc. MKP1 has been shown to dephosphorylate, and
thereby inactivate, the ERK, JNK, and p38 MAP kinases (22,
42, 57, 73). Activated Cdc42, Rac1, and RhoA stimulated lu-
ciferase reporter gene expression (Fig. 8B). Coexpression of
MKP1 markedly reduced the effect of the Rho family GTPases
to activate GAL4–Elk-1-dependent luciferase expression (Fig.
8B). These data demonstrate that Rho family GTPase signal-
ing to Elk-1 requires MAP kinase activation. Mutation of a
MAP kinase phosphorylation site (Ser-383) known to be crit-
ical for MAP kinase-stimulated Elk-1 transcriptional activity
(10, 18, 20, 31, 47, 58, 82) greatly reduced Rho family GTPase
stimulation of Elk-1 transcriptional activity (Fig. 8B). Togeth-
er, these data indicate that Rho family GTPases are compo-
nents of MAP kinase pathways leading to increased Elk-1
transcriptional activity.
To determine whether the Rho family GTPases Cdc42,
Rac1, and RhoA play a role in the signaling pathways that
mediate IL-1-induced Elk-1 transcriptional activity, we trans-
fected CHO cells with plasmids expressing inactivated forms of
Cdc42, Rac1, and RhoA GTPases, GAL4–Elk-1, and the re-
porter plasmid pG5E1bLuc. We subsequently treated the cells
with IL-1 and measured the reporter luciferase expression
(Fig. 8C). The inactivated Cdc42, Rac1, and RhoA mutants
blocked IL-1 signaling to Elk-1, indicating their potential in-
volvement in IL-1-stimulated Elk-1 transcriptional activity.
However, the inactivated Rho-GTPases may bind to endoge-
nous factors, such as guanine nucleotide exchange factors,
which are common to other small GTP binding proteins, and
thereby inhibit their action. Further studies are required to
provide direct evidence for a role of Rho family GTPases in
IL-1 signal transduction.
The JNK MAP kinase signaling pathway mediates Cdc42
GTPase regulation of Elk-1 transcriptional activity in CHO
cells. Rho family GTPases are established to activate JNK and
p38 MAP kinases in CHO cells (Fig. 7B), leading to transcrip-
tional activation of Elk-1 (Fig. 8B). We therefore used the
selective inhibitors of the p38 and JNKMAP kinase pathway to
differentiate between the respective roles of JNK and p38
MAP kinases in the regulation of Elk-1 transcriptional activity
by the Rho family GTPase Cdc42. DN-MKK4 inhibited Cdc42-
mediated activation of the transcriptional activity of both Elk-1
and the JNK substrate c-Jun (Fig. 8D). In control experiments
using activated Ras, DN-MKK4 did not block Ras signaling to
Elk-1 (mediated by the ERK pathway) but did block Ras
signaling to c-Jun (mediated by the JNK pathway) (Fig. 8E).
Incubation of transfected cells with the p38 inhibitor drug
VK19577 did not result in inhibition of Cdc42-mediated acti-
vation of Elk-1 or c-Jun. Control studies demonstrate that this
drug did inhibit p38 MAP kinase signaling under these condi-
tions (Fig. 4). Together, these data indicate that in CHO cells,
Cdc42-regulated Elk-1 transcriptional activity is mediated pri-
marily through the JNK MAP kinase signal transduction path-
way and that Rho family GTPases such as Cdc42 may be a link
between activated IL-1 receptors and the JNK MAP kinase
cascade.
DISCUSSION
Elk-1 and SAP-1 are activated by distinct groups of MAP
kinases. The c-fos SRE is activated by a wide array of stimuli
mediated by pathways leading to the TCF and SRF compo-
nents of the ternary complex (7, 8). The TCF protein Elk-1 is
a target for the MAP kinases ERK (18, 19, 31), JNK (10, 20,
82, 88), and p38 (58). The related TCF protein SAP-1 is tar-
geted by ERK MAP kinase (30, 54, 58, 70). Here we demon-
strate that both Elk-1 and SAP-1 are phosphorylated by p38
MAP kinase (Fig. 1), leading to increased ternary complex
formation (Fig. 2), DNA binding activity (Fig. 2), and tran-
scriptional activation (Fig. 4). The transcription factors Elk-1
and SAP-1 therefore serve to integrate signals from multiple
MAP kinase pathways in response to extracellular stimuli (Fig.
1, 2, and 4 and references 10, 18 to 20, 31, 47, 58, 82, and 88).
SAP-1 is a poor substrate for JNK MAP kinase in vitro (82).
The selective targeting of Elk-1 compared to SAP-1 by JNK
MAP kinase may allow for differential responses of the SRE to
particular stimuli depending on the composition of the ternary
complex. Interestingly, Elk-1 and SAP-1 display different spec-
ificities of DNA binding to various ets-related sites in vitro (68,
70). Promoters may therefore be targeted by different TCF
proteins depending on their DNA binding specificities and the
MAP kinases that phosphorylate them.
IL-1 and Cdc42 GTPase signaling to Elk-1 requires the JNK
MAP kinase pathway in CHO cells. While both the p38 and
JNK pathways are capable of targeting TCF proteins, it is
unclear which pathways are utilized by particular extracellular
stimuli. We used the recently described p38 inhibitor VK19577
(also termed SB203580) as a tool to elucidate the pathways
involved in IL-1 signaling to TCFs. This drug inhibits both p38
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MAP kinase and particular JNK isoform protein kinase activ-
ities in vitro (Fig. 3). However, careful titration allows specific
inhibition of p38 protein kinase activity (Fig. 3). In CHO cells,
the drug inhibits activation of Elk-1 and SAP-1 by the p38
MAP kinase signaling pathway (mediated by MKK3 and
MKK6) but does not inhibit Elk-1 and SAP-1 activation by
alternative MAP kinase pathways (mediated by MEK1 and
MEKK1) (Fig. 4). MEK1 is a component of the ERK MAP
kinase signaling pathway (15, 81), while MEKK1 is a compo-
nent of the JNK MAP kinase signaling pathway (50, 84).
Therefore, under controlled experimental conditions, the p38
inhibitor drug VK19577 does not appear to inhibit ERK or
JNK signaling in vivo. Interestingly, expression of MEKK1
increases SAP-1-dependent reporter gene expression in these
assays (Fig. 4). As SAP-1 is a poor substrate for JNK MAP
kinase (82), this result suggests that MEKK1 activates a novel
signaling pathway that targets SAP-1.
IL-1 increases JNK and p38 MAP kinase activity (Fig. 5C
and reference 57) and the transcriptional activity of Elk-1 and
SAP-1 in CHO cells (Fig. 5A and reference 82). Rho family
GTPases also regulate the JNK and p38 MAP kinase signaling
pathways (Fig. 7 and references 2, 11, 49, 53, and 86). How-
ever, a previous study of NIH 3T3 cells indicated that Rho
family GTPases activate SRF (and not Elk-1), leading to in-
creased SRE-dependent gene expression, and that the ERK,
JNK, and p38 MAP kinases are not involved in mediating this
effect (27). Here we demonstrate that in CHO cells the Rho
family GTPases are involved in signaling pathways leading to
increased SRE-dependent gene expression mediated by Elk-1
(Fig. 8). Activated forms of Cdc42, Rac1, and RhoA cause
FIG. 8. Rho family GTPases signal to Elk-1 and the SRE in CHO cells. (A) Rho family GTPases regulate SRE-dependent gene expression via MAP kinases in CHO
cells. Cells were transfected with the pSRE-Luc reporter plasmid (1 mg) together with plasmids expressing activated Rho family GTPases (0.5 mg). The effect of MKP1
expression (0.5 mg of expression vector transfected) was examined. Transfection efficiency was monitored by using the b-galactosidase expression vector pCH110 (0.1
mg). The relative luciferase activities (means6 standard deviations; n5 3) are presented. (B) Rho family GTPases regulate activation of Elk-1 via MAP kinase pathways
in CHO cells. The effect of expression of MKP1 (0.5 mg of expression vector transfected) and activated Rho family GTPases (0.5 mg of expression vectors transfected),
and the mutation of a critical MAP kinase phosphorylation site in Elk-1 (Ser-383 to Ala), on GAL4–Elk-1-mediated luciferase gene expression from the reporter
plasmid pG5E1bLuc was examined. The data are presented as relative luciferase activities (means 6 standard deviations; n 5 3). (C) Dominant-negative mutants of
Cdc42, Rac1, and RhoA inhibit IL-1-stimulated gene expression mediated by Elk-1. CHO cells were transfected with the pG5E1bLuc reporter plasmid (0.25 mg), an
expression vector for GAL4-Elk-1 (0.25 mg), and an expression vector for either inactivated Cdc42 (DN-Cdc42), inactivated Rac1 (DN-Rac1), or inactivated RhoA
(DN-RhoA) (0.5 mg of each). The b-galactosidase expression vector pCH110 was included as a control for transfection efficiency. The cells were transferred 24 h
following transfection to serum-free medium for a further 12 h. The cells were then treated with or without 10 ng of IL-1 per ml in serum-free medium for 10 h. Cell
extracts were prepared, and the luciferase and b-galactosidase activities were measured. The data are presented as relative luciferase activities (means 6 standard
deviations; n 5 3). (D) Requirement of JNK, but not p38 MAP kinase, for Cdc42-stimulated Elk-1 transcriptional activity in CHO cells. CHO cells were cotransfected
with a b-galactosidase expression vector (pCH110), the reporter plasmid pG5E1bLuc (0.25 mg), and expression vectors for either GAL4-Elk-1 or GAL4-cJun (0.25 mg).
Where indicated, plasmids expressing activated Cdc42 GTPase (Cdc42 L61) (0.5 mg) and DN-MKK4 (0.5 mg) were included in the transfections, or the cells were
treated with 10 mM p38 inhibitor VK19577 (Drug). Cell extracts were prepared 48 h following transfection, and the luciferase and b-galactosidase activities were
measured. The data are presented as relative luciferase activities (means 6 standard deviations; n 5 3). (E) CHO cells were transfected as in panel D except that a
vector expressing activated Ras GTPase (Ras L61) (0.1 mg) was used instead of activated Cdc42 GTPase.
2368 WHITMARSH ET AL. MOL. CELL. BIOL.
 at UNIV O
F M
ASS M
ED SCH on August 15, 2008 
m
cb.asm
.org
D
ow
nloaded from
 
increased Elk-1 transcriptional activation (Fig. 8B) and SRE-
dependent gene expression (Fig. 8A). The MAP kinase phos-
phatase MKP1 markedly inhibits Rho family GTPase-medi-
ated Elk-1 activation, suggesting that Rho family members
signal to Elk-1 exclusively via MAP kinase pathways (Fig. 8B).
However, SRE-dependent transcription is only partially inhib-
ited by MKP1 (Fig. 8A), indicating that a component of the
activation of SRE-dependent gene expression may not involve
MAP kinases. This pathway may be accounted for by signals
from Rho family GTPases that activate SRF (27). The appar-
ent discrepancy between our results demonstrating a previ-
ously unreported link between Rho family GTPases and TCFs
and those recently described (27) could be due to the different
cell lines used in these experiments. Distinct signaling mecha-
nisms may be utilized by Rho family GTPases in different cell
lines.
To address the respective roles of JNK and p38 MAP ki-
nases in IL-1- and Rho family GTPase-mediated Elk-1 tran-
scriptional activity, we examined the effects of the p38 inhibitor
drug VK19577 and the expression of DN-MKK4 on IL-1- and
Cdc42-induced GAL4-Elk-1-dependent reporter gene expres-
sion in CHO cells. DN-MKK4 inhibited IL-1-stimulated (Fig.
5A) and Cdc42-stimulated (Fig. 8D) Elk-1-dependent tran-
scriptional activity whereas the drug VK19577 did not, indicat-
ing that the JNK group of MAP kinases is required for IL-1-
and Cdc42-stimulated Elk-1 activation. Taken together with
the data demonstrating that inactivated forms of Cdc42, Rac1,
and RhoA block IL-1-induced activation of Elk-1 in CHO cells
(Fig. 8C), these results suggest that IL-1 signaling to Elk-1 in
CHO cells may be mediated by Cdc42 (and/or other Rho
family GTPases) and the JNK MAP kinase signal transduction
pathway.
Neither the p38 inhibitor drug VK19577 nor DN-MKK4
inhibited the IL-1-induced transcriptional activity of SAP-1 in
CHO cells (Fig. 5A). These data indicate that the p38 and JNK
MAP kinase signaling pathways are not essential for mediating
the effects of IL-1 on SAP-1 transcriptional activity. This IL-1
signaling to SAP-1 therefore occurs via a novel signaling path-
way in CHO cells. This novel pathway may involve MEKK1,
since MEKK1 induces SAP-1 transcriptional activity (Fig. 4).
c-fos SRE-dependent reporter gene expression was inhibited
in CHO cells by coexpression of DN-MKK4 but not by treat-
ment with the drug VK19577. This result suggests that Elk-1,
rather than SAP-1, may be a major component of ternary
complexes formed at the c-fos SRE in CHO cells. However,
other ternary complex factors and SRE or SRF binding pro-
teins may also participate in transcriptional regulation of the
c-fos SRE.
The p38 and JNK MAP kinase signaling pathways are re-
quired for IL-1 signaling to Elk-1 in NIH 3T3 cells. Consider-
ing that IL-1 activates both JNK and p38 MAP kinases and
that TCF proteins are targets of both the JNK and p38 MAP
kinase signal transduction pathways, it seemed plausible that
the signaling pathways utilized by IL-1 to activate TCFs may
depend on cell type. To test this hypothesis, we examined NIH
3T3 cells, which have been extensively used in studies of signal
transduction pathways converging at the SRE (76). In direct
contrast to CHO cells, the p38 inhibitor drug VK19577 inhibits
IL-1-induced Elk-1 and SAP-1 transcriptional activities in NIH
3T3 cells (Fig. 6A). Therefore, the p38 MAP kinase signaling
pathway is required for IL-1-induced activation of these TCF
proteins in NIH 3T3 cells. DN-MKK4 blocks IL-1 signaling to
Elk-1 (but not SAP-1), indicating that in this cell type, both the
p38 and JNK MAP kinase signaling pathways are required to
mediate full transcriptional activation of Elk-1 by IL-1. The
JNK and p38 MAP kinase signaling pathways may therefore be
selectively utilized in different cell types to activate TCF pro-
teins in response to treatment with IL-1.
Convergence of MAP kinase signaling pathways at the SRE.
The c-fos SRE is a site of integration of multiple signal trans-
duction pathways in response to a variety of extracellular stim-
uli. A component of this regulation involves the TCF proteins
Elk-1 and SAP-1 that are activated by MAP kinases. Elk-1 and
SAP-1 can be regulated by the ERK and p38 MAP kinase
signal transduction pathways, while JNK MAP kinase selec-
tively targets Elk-1. ERK, JNK, and p38 MAP kinases phos-
phorylate sites within the COOH-terminal activation domain
of these TCFs, leading to enhanced SRE-dependent transcrip-
tion. The potential signaling routes to the SRE mediated by
MAP kinases are depicted in Fig. 9. In response to growth
factors, Ras activates a pathway that leads to the ERK group of
MAP kinases via Raf-1 and MEK. Ras may also have a role in
JNK MAP kinase activation (16), either directly upstream of
MEKK1 (61) or by activating Rac1 and RhoA. Cdc42, Rac1,
and RhoA activate the JNK and p38 MAP kinase pathways
leading to the regulation of TCF transcriptional activity. In
addition, RhoA regulates SRF transcriptional activity by a
pathway that appears to be independent of Cdc42 and Rac1
regulation of SRF activity (27). The components of the path-
ways that activate SRF remain to be elucidated.
Both JNK and p38 MAP kinase pathways contribute to IL-1
signaling to TCFs. We have provided evidence that both JNK
and p38 MAP kinase signal transduction pathways can target
TCF proteins and the SRE in response to treatment with IL-1.
Induction of Elk-1 transcriptional activity by IL-1 can be me-
diated by the JNK and/or p38 MAP kinase signaling pathways
depending on the cell type. This differential utilization of MAP
kinase signaling pathways represents one potential mechanism
for the determination of cell-type-specific responses to extra-
cellular stimuli. A goal for future studies will be to define the
molecular basis of the cell-type-specific targeting of MAP ki-
FIG. 9. Rho family GTPase-mediated signal transduction to the c-fos SRE. A
complex of SRF and TCF binds to the c-fos SRE and mediates increased gene
expression in response to extracellular stimuli (7, 8). The Rho family GTPases
Cdc42, Rac1, and RhoA mediate JNK and p38 MAP kinase activation. Ras can
also partially activate JNK and p38, possibly through Rac1 and RhoA (35, 36, 55,
56) or MEKK1 (61). Ras strongly activates the ERK MAP kinase pathway (15).
Activated ERK, JNK, and p38 MAP kinases phosphorylate TCF/Elk-1, leading
to increased transcriptional activation. Cdc42/Rac1 and RhoA are also compo-
nents of signaling pathways that may regulate SRF transcriptional activity (27).
Rho family GTPases are therefore involved in distinct signal transduction path-
ways which regulate SRE-dependent transcription through TCF/Elk-1 and SRF.
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nase signaling pathways to TCF proteins in vivo. Targeting of
MAP kinase signaling pathways by protein-protein interactions
may account for this signaling specificity. Current studies in
this laboratory are designed to test this hypothesis.
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